New prognostic biomarker CMTM3 in low grade glioma and its immune infiltration

Li, Shoubin; Gao, Peng; Ye, Lei; Wang, Zhongyong; Cheng, Hongwei

doi:10.21037/atm-22-526

Cited by 9 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients with LGG inevitably progress to high-grade glioma (HGG) ( Duffau, 2018 ). Various treatment methods, such as surgery, radiotherapy, chemotherapy, immunotherapy, electric field therapy, and neutron therapy are used, but tumor recurrence appears to be unavoidable ( Lu et al, 2021 ; Li et al, 2022 ). Therefore, it is urgent to identify novel potential therapeutic targets for LGG.…”

Section: Introductionmentioning

confidence: 99%

A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma

Yan

Wang²,

Dong³

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Cuproptosis is a new type of cell death that is associated with mitochondrial respiration of the tricarboxylic acid cycle. Previous studies showed that long non-coding RNAs (lncRNAs) regulated low-grade glioma (LGG) progression. However, the potential applications of cuproptosis-related lncRNAs (CRLs) in LGG were not explored. A comprehensive analysis was performed in The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) cohorts. We first screened two distinct cuproptosis subtypes based on prognostic CRLs using consensus clustering. To facilitate individualized survival prediction in LGG, we constructed a prognostic signature (including CRNDE, HAR1A, and FAM181A-AS1) in the TCGA dataset. The prognostic signature exhibited excellent predictive ability and reliability, which was validated in the CGGA_325 and CGGA_693 datasets. Notably, patients in the high-risk group had increased immune cell infiltration and expression of immune checkpoints, which indicated that they may benefit more from immune checkpoint blockade (ICB) therapy. Finally, the prognostic signature screened the population with sensitivity to chemotherapy and ICB therapy. In summary, this study initially explored the mechanism of CRLs in LGG and provides some insights into chemotherapy and ICB therapy of LGG.

show abstract

Section: Introductionmentioning

confidence: 99%

A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma

Yan

Wang²,

Dong³

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Although standard treatment is available, LrGG generally transforms into high‐grade glioma within 4–5 years after diagnosis 28 . Owing to the significant heterogeneity of LrGG, patients are often resistant to conventional treatment 29,30 . Consequently, prognosis prediction and individualized treatment strategies are difficult to achieve.…”

Section: Discussionmentioning

confidence: 99%

“…28 Owing to the significant heterogeneity of LrGG, patients are often resistant to conventional treatment. 29,30 Consequently, prognosis prediction and individualized treatment strategies are difficult to achieve.…”

Section: Discussionmentioning

confidence: 99%

Cuproptosis‐related classification and personalized treatment in lower‐grade gliomas to prompt precise oncology

Shen

Chen

Liu

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background: Cuproptosis is implicated in regulating tricarboxylic acid cycle and associated with tumor therapeutic sensitivity, patient outcomes and tumorigenesis. However, the classification and prognostic effect of cuproptosis-associated genes (CAGs), the relationship between cuproptosis and tumor microenvironment (TME) and the treatment of lower-grade glioma (LrGG) remain enigmatic. Methods: The genetic and transcriptional alterations, prognostic value and classification related to cuproptosis were systematically analyzed. Subtypes of cuproptosis and cuproptosis score (Cuscore) were constructed and further confirmed by two external cohorts. The relationships between cuproptosis and TME, prognosis, and treatment response were also evaluated. Results: Four clusters were identified based on cuproptosis-associated genes. The associations between cuproptosis-associated clusters and clinical features, prognosis, immune cell infiltration, and chemotherapy sensitivity were observed. The Cuscore is an independent prognostic indicator in LrGG patients. The nomogram is constructed according to Cuscore and clinical characteristics, and has good predictive ability and calibration. Patients with high Cuscore had a worse prognosis and advanced performance. A higher Cuscore also indicated a higher stromal score, abundant immune infiltration, and increased tumor mutation burden. A high Cuscore was remarkably related to immune checkpoint inhibitors, immunotherapy response and immune phenotype.Conclusions: This study demonstrates the clinical effect of CAGs, and suggests that cuproptosis could be a potential therapeutic target in LrGG.

show abstract

“…Li et al found that CMTM3 was significantly associated with a variety of immune cells in the immune microenvironment, such as macrophages and dendritic cells in high-grade gliomas, and was also associated with prognosis. High expression of CMTM3 was associated with a poorer prognosis [42]. Fan et al reported that Pfn-1 phosphorylation is involved in the regulation of endothelial vasculin expression and promotes abnormal vascularization and GBM development through a hypoxy-independent HIF-1α induction mechanism [43].…”

Section: Discussionmentioning

confidence: 99%

lncRNA TRHDE-AS1 Correlated with Genomic Landscape and Clinical Outcome in Glioma

Xie

Lin

et al. 2023

Genes

View full text Add to dashboard Cite

The role of lncRNA in cancer development has received more and more attention in research. A variety of lncRNAs are associated with the occurrence and development of glioma. However, the role of TRHDE-AS1 in glioma is still unknown. In this study, we explored the role of TRHDE-AS1 in glioma through bioinformatic methods. We first identified an association between TRHDE-AS1 and tumor prognosis in pan-cancer analysis. Subsequently, the expression levels of TRHDE-AS1 in various clinical types of glioma were compared, and significant differences were found in pathological classification, WHO classification, molecular classification, IDH mutation, and age stratification. We analyzed the genes co-expressed with TRHDE-AS1 in glioma. In the functional analysis of TRHDE-AS1, we found that TRHDE-AS1 may be involved in the regulation of synapse-related functions. In glioma cancer driver gene correlation analysis, it was also found that TRHDE-AS1 was significantly correlated with the expression levels of multiple driver genes such as TP53, BRAF, and IDH1. By comparing the mutant profiles of the high and low TRHDE-AS1 groups, we also found that there may be differences in TP53 and CIC gene mutations in low-grade gliomas. Subsequent correlation analysis between TRHDE-AS1 and glioma immune microenvironment showed that the expression level of TRHDE-AS1 was correlated with a variety of immune cells. Therefore, we believe that TRHDE-AS1 is involved in the occurrence and development of glioma and has the ability to predict the prognosis of glioma as a biomarker of glioma.

show abstract

New prognostic biomarker CMTM3 in low grade glioma and its immune infiltration

Cited by 9 publications

References 23 publications

A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma

A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma

Cuproptosis‐related classification and personalized treatment in lower‐grade gliomas to prompt precise oncology

lncRNA TRHDE-AS1 Correlated with Genomic Landscape and Clinical Outcome in Glioma

Contact Info

Product

Resources

About